Results for covaxin

Add to feed Create your own feed

Latest

Bharat Biotech and ICMR publish interim phase 3 trial data, Covaxin shows 100% efficacy against serious CovidSneha Mordani with more details #ITVideo  #Covid19  #Covaxin  #CoronaVaccine  | @snehamordani 

Bharat Biotech's #Covaxin  78% effective; works against most #COVID19  variants @joecmathew  #coronavirusvaccine 

Just in | #BharatBiotech  has reported an updated efficacy of 78% of Covaxin. The efficacy against severe disease was 100% and against asymptomatic transmission 70%. - @neutranino  reports.

Bharat BiotechCOVAXINAnnouncement Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of #COVAXIN ®️; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe#COVID19  disease.

tweet picture

ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the apex health research body said.

Covaxin effective against double mutant strain found in India: ICMR study

tweet picture

Covaxin phase 3 trials show interim clinical efficacy of 78%

Covaxin effective against UK strain, double mutant variant: ICMR

Loading
Loading

Most relevant

ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well: Indian Council of Medical Research (ICMR) #COVID19 

tweet picture

Rajasthan: 320 doses of COVAXIN missing from cold storage of Hari Bux Kanwatia Govt hospital, Jaipur. FIR registered. Nodal Officer of the vaccination centre here says, "There's systematic record of doses coming at centre. So it's suspected that vaccines went missing from store."

COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech

tweet picture

#WATCH : Prime Minister Narendra Modi took his first dose of th #COVID19  vaccine at AIIMS Delhi today. He was administered Bharat Biotech's COVAXIN.

Bharat Biotech confirms deal with Brazil to supply 20 million doses of COVAXIN vaccine

tweet picture

Covaxin has shown less than 10 % adverse reactions, while others have 60-70% adverse reactions.AstraZeneca was giving 4g paracetamol to volunteers to suppress such reactions. We haven’t given paracetamol to any volunteer. I can assure our vaccine is a 200 % safe:Bharat Biotech MD

tweet picture

There were no seroconversions in those who were provided vaccines in Phase II as well as Phase I of COVAXIN clinical trials. @ICMRDELHI  @MoHFW_INDIA  @icmr_niv  @DBTIndia  @BharatBiotechLt 

tweet picture

The data from COVAXINPhase I & II clinical trials reveals that it not only produces neutralizing antibodies in all participants but also sensitises  CD4 T lymphocytes that imparts durable immune response @BharatBiotechL  @PMOIndiat  @ICMRDELHI  @icmr_niv  @MoHFW_INDIA  @DBTIndia 

tweet picture

For those spreading rumours let it be known that EUA for COVAXIN is differently conditional – in clinical trial mode EUA for COVAXIN is different from COVISHIELD because its use will be in clinical trial mode. All COVAXIN recipients to be tracked,monitored as if they’re in trial

tweet picture

COVAXIN is more likely to work against newer variants like N501Y Variant (UK variant) & any other that may arise due to antigenic drift as it contains immunogens (epitopes) from other genes in addition to those from Spike protein Inactivated virus from NIV also had D614G mutation

tweet picture

Loading
Loading